Trial Profile
Phase II Trial of Pentostatin, Cyclophosphamide and Rituximab (PCR) Followed by Campath-1H for Previously Treated Relapsed or Refractory Patients With Chronic Lymphocytic Leukemia
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 03 Jul 2023
Price :
$35
*
At a glance
- Drugs Cyclophosphamide (Primary) ; Lenalidomide (Primary) ; Pentostatin (Primary) ; Rituximab (Primary) ; Alemtuzumab; Filgrastim; Pegfilgrastim
- Indications Chronic lymphocytic leukaemia
- Focus Therapeutic Use
- 06 Feb 2019 Status changed from recruiting to completed.
- 18 Jul 2012 Planned End Date changed from 1 Jun 2009 to 1 Oct 2014 as reported by ClinicalTrials.gov.
- 05 Oct 2009 New source identified and integrated (New Jersey Cancer Trial Connect record, ECOG2903).